The FDA is requiring the three manufacturers of the COVID-19 vaccines it approved today to conduct a variety of postmarketing studies.

The approval letter to Pfizer and its BioNTech mentions the companies' commitment to conduct four postmarketing studies of their vaccine, marketed under the brand name Comirnaty. The two approval letters to Moderna, one for its Spikevax vaccine and another for an updated version marketed as Mnexspike, mention a total of four postmarketing trials.

The letter to Novavax, the maker of the third approved vaccine, Nuvaxovid, mentions the company’s commitment to conducting two postmarketing studies.

FDA Commissioner Martin A. Makary, M.D., M.P.H., and Vinay Prasad, M.D., M.P.H., director of the FDA’s Center for Biologics Evaluation and Research (CBER), indicat

See Full Page